Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors
Withdrawn
- Conditions
- Brain Tumor, Pediatric
- Registration Number
- NCT04019470
- Lead Sponsor
- Capital Medical University
- Brief Summary
To investigate the effect of radiotherapy on peripheral blood immune cell composition and function in pediatric malignant brain tumor patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Age from 3 to 18
- To be diagnosed with malignant brain tumors
- To eligible for radiation therapy
- Karnofsky performance status ≥ 70
- No prior radiation exposure
- Informed consent signed for blood sample collection and used for research purpose
Exclusion Criteria
- Patients had received radiotherapy previously.
- Patients who had no histological diagnosis
- Patients who do not wish to participate
- Patients with infections
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The changes of peripheral blood immune cells 6 weeks (prior and post the radiation therapy ) The flow cytometric analysis of lymphocyte subtypes populations would be performed
- Secondary Outcome Measures
Name Time Method The changs of inflammatory cytokines and chemokines 6 weeks (prior and post the radiation therapy ) Human inflammatory cytokines and chemokines will be analyzed by ELISA during radiation therapy. The cytokines and chemokines are IL-2, IL-10, IFN-γ, TNF-α
Activation status of T cells 6 weeks (prior and post the radiation therapy ) Activation status of peripheral IFN-γ-producing effector CD8+ T cells by Elispot.
Trial Locations
- Locations (1)
Beijing Shijitan Hospital Cancer Center
🇨🇳Beijing, China